Prolonged Interleukin-2 (IL-2) Treatment Can Augment Immune Activation Without Enhancing Antitumor Activity in Renal Cell Carcinom

Jeff A. Sosman Departments of Human Oncology, Statistics, Pediatrics and Genetics, University of Wisconsin, Department of Medicine, Madison General Hospital, Madison, Wisconsin, 53715; The Clinical Investigation Section, Hoffman LaRoche, Inc., Nutley, New Jersey, 07011; The Section of Hematology/Oncology, Department of Medicine, Loyola University Stritch School of Medicine, Maywood, Illinois, 60153

Jacquelyn A. Hank Departments of Human Oncology, Statistics, Pediatrics and Genetics, University of Wisconsin, Department of Medicine, Madison General Hospital, Madison, Wisconsin, 53715; The Clinical Investigation Section, Hoffman LaRoche, Inc., Nutley, New Jersey, 07011; The Section of Hematology/Oncology, Department of Medicine, Loyola University Stritch School of Medicine, Maywood, Illinois, 60153

Karen H. Moore Departments of Human Oncology, Statistics, Pediatrics and Genetics, University of Wisconsin, Department of Medicine, Madison General Hospital, Madison, Wisconsin, 53715; The Clinical Investigation Section, Hoffman LaRoche, Inc., Nutley, New Jersey, 07011; The Section of Hematology/Oncology, Department of Medicine, Loyola University Stritch School of Medicine, Maywood, Illinois, 60153

Agnes Borchert Departments of Human Oncology, Statistics, Pediatrics and Genetics, University of Wisconsin, Department of Medicine, Madison General Hospital, Madison, Wisconsin, 53715; The Clinical Investigation Section, Hoffman LaRoche, Inc., Nutley, New Jersey, 07011; The Section of Hematology/Oncology, Department of Medicine, Loyola University Stritch School of Medicine, Maywood, Illinois, 60153

Kathleen Schell Departments of Human Oncology, Statistics, Pediatrics and Genetics, University of Wisconsin, Department of Medicine, Madison General Hospital, Madison, Wisconsin, 53715; The Clinical Investigation Section, Hoffman LaRoche, Inc., Nutley, New Jersey, 07011; The Section of Hematology/Oncology, Department of Medicine, Loyola University Stritch School of Medicine, Maywood, Illinois, 60153

Peter C. Kohler Departments of Human Oncology, Statistics, Pediatrics and Genetics, University of Wisconsin, Department of Medicine, Madison General Hospital, Madison, Wisconsin, 53715; The Clinical Investigation Section, Hoffman LaRoche, Inc., Nutley, New Jersey, 07011; The Section of Hematology/Oncology, Department of Medicine, Loyola University Stritch School of Medicine, Maywood, Illinois, 60153

David Goldstein Departments of Human Oncology, Statistics, Pediatrics and Genetics, University of Wisconsin, Department of Medicine, Madison General Hospital, Madison, Wisconsin, 53715; The Clinical Investigation Section, Hoffman LaRoche, Inc., Nutley, New Jersey, 07011; The Section of Hematology/Oncology, Department of Medicine, Loyola University Stritch School of Medicine, Maywood, Illinois, 60153

Robin Bechhofer Departments of Human Oncology, Statistics, Pediatrics and Genetics, University of Wisconsin, Department of Medicine, Madison General Hospital, Madison, Wisconsin, 53715; The Clinical Investigation Section, Hoffman LaRoche, Inc., Nutley, New Jersey, 07011; The Section of Hematology/Oncology, Department of Medicine, Loyola University Stritch School of Medicine, Maywood, Illinois, 60153

Barry Storer Departments of Human Oncology, Statistics, Pediatrics and Genetics, University of Wisconsin, Department of Medicine, Madison General Hospital, Madison, Wisconsin, 53715; The Clinical Investigation Section, Hoffman LaRoche, Inc., Nutley, New Jersey, 07011; The Section of Hematology/Oncology, Department of Medicine, Loyola University Stritch School of Medicine, Maywood, Illinois, 60153

Mark R. Albertini Departments of Human Oncology, Statistics, Pediatrics and Genetics, University of Wisconsin, Department of Medicine, Madison General Hospital, Madison, Wisconsin, 53715; The Clinical Investigation Section, Hoffman LaRoche, Inc., Nutley, New Jersey, 07011; The Section of Hematology/Oncology, Department of Medicine, Loyola University Stritch School of Medicine, Maywood, Illinois, 60153

Pearl E. Leung Departments of Human Oncology, Statistics, Pediatrics and Genetics, University of Wisconsin, Department of Medicine, Madison General Hospital, Madison, Wisconsin, 53715; The Clinical Investigation Section, Hoffman LaRoche, Inc., Nutley, New Jersey, 07011; The Section of Hematology/Oncology, Department of Medicine, Loyola University Stritch School of Medicine, Maywood, Illinois, 60153

Daniel Levitt Departments of Human Oncology, Statistics, Pediatrics and Genetics, University of Wisconsin, Department of Medicine, Madison General Hospital, Madison, Wisconsin, 53715; The Clinical Investigation Section, Hoffman LaRoche, Inc., Nutley, New Jersey, 07011; The Section of Hematology/Oncology, Department of Medicine, Loyola University Stritch School of Medicine, Maywood, Illinois, 60153

Paul M. Sondel Departments of Human Oncology, Statistics, Pediatrics and Genetics, University of Wisconsin, Department of Medicine, Madison General Hospital, Madison, Wisconsin, 53715; The Clinical Investigation Section, Hoffman LaRoche, Inc., Nutley, New Jersey, 07011; The Section of Hematology/Oncology, Department of Medicine, Loyola University Stritch School of Medicine, Maywood, Illinois, 60153

show all

Prolonged Interleukin-2 (IL-2) Treatment Can Augment Immune Activation Without Enhancing Antitumor Activity in Renal Cell Carcinom

Articles from other publishers (9)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Prolonged Interleukin-2 (IL-2) Treatment Can Augment Immune Activation Without Enhancing Antitumor Activity in Renal Cell Carcinom

Citations (11)

Read on this site (2)

Articles from other publishers (9)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date